Drug Candidate Marketplace
Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs and download the list. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. Additional information will be provided to you.
|Date||Candidate||Mechanism of action||Indication||Route||Modality||Development stage||Note|
|06/04/18||GEM019||3rd generation immunotherapy targeting HER2||HER2 overexpressing cancer （Breast）||SC||Proteins
||Preclinical||-Applied 3rd generation immunotherapy technology to HER2.
-Superior efficacy to trastuzumab and pertuzumab.
-In-vivo PoC has been validated in non-human primates.
|06/04/18||GEM018||3rd generation immunotherapy technology||Cancer||SC||Proteins
||Discovery||-Unique technology that triggers B and T cells simultaneously while activating all possible natural tumor killing mechanisms available to the immune-system.
-Tumor-directed specific activation reduces side effects to the minimum.
-Applicable on a target basis.
|04/10/18||GEM008||Selective cMET inhibitor||NSCLC and HCC etc.||Oral||Small molecules
||Phase 2||Effective on exon 14 skipping xenograft
Development by an originator has been discontinued.